Nylexa (NM002)

Antibiotic resistance is a major health threat worldwide. An existing problem only set to worsen as demonstrated by the current COVID-19 pandemic.

NM002 (Nylexa®) is a potential solution to the worsening antibiotic resistance crisis and a strategy that could be introduced into clinical practice within a much shorter timescale than any new antibiotic(s) developed from first principle. 

Derived from NovaBiotics aminothiol platform Nylexa® is an antibiotic potentiator/resistance breaking agent being developed as an adjunct (intravenous and oral) to a number of antibiotic classes; extending their utility and scope against drug resistant, even MDR and XDR bacterial infections. Put simply, Nylexa ‘supercharges’ existing antibiotics, especially against drug resistant bacteria.  In vitro and in vivo data generated thus far have demonstrated Nylexa’s efficacy in a number of infection models, supported and re-risked by Lynovex® clinical data.

We must increase the supply of new antimicrobials effective against drug-resistant drugs

Nylexa and COVID-19

NM002 (Nylexa) has potential application in a number of serious, life threatening bacterial infections.  Data from the COVID-19 outbreak points however to the urgent need to develop Nylexa for respiratory (lung) infections in the first instance.

Viral infections of the lungs (including influenza, coronavirus) are known to predispose those affected to secondary bacterial infections.  The virus ‘diverts’ the body’s immune system and therefore the ability to fight bacterial infections at the same time as the virus.  This means the bacteria can successfully establish an often very serious chest infection (secondary pneumonia).  More than half the patients who died after contracting COVID-19 in Wuhan, Hubei province (China), succumbed to a lung bacterial infection and sepsis, despite having antibiotic treatment.  The percentage of secondary bacterial infections in COVID-19 appears to be higher than for other respiratory viral infections.  Using Nylexa alongside often ineffective antibiotics in COVID-19 patients either at high risk of, or known to already have, a secondary lung bacterial infection can boost the antibiotics effects and help clear the lungs.

Nylexa could save the lives of COVID-19 patients with the most serious secondary bacterial pneumonia and aid better recovery even in those patients with less severe disease. 

Key antibiotic facts*:

Review on Antimicrobial Resistance report, 19 May 2016 – key findings

 

  • 700,000 deaths (current rate) globally every year are attributed to antimicrobial resistance (AMR).
  • By 2050, the death rate could be as high as 10 million per year – that’s one person every 3 seconds.
  • Development of new drugs and improvement of existing ones is key in the fight against AMR
  • By 2050, the cost of AMR could be as high as $100 trillion meaning every person alive in the world today will be $10,000 worse off.
  • The estimated cost of global action to fight AMR is estimated to be $40 billion over a 10 year period.
  • In the US alone, there are more than 2 million infections per year, costing the US Healthcare system in excess of $20 billion per year.
  • During the ‘golden era’ of antibiotic discovery in the 1940s and 1950s saw a steady stream of products coming to market, today’s total antibiotics pipeline is fewer than 50.
  • Between 2003 – 2013, less than 5% of VC investment in pharmaceutical R&D was for antimicrobial development.

 

*O’Neill ‘Review on Antimicrobial Resistance’ report, 19 May 2016 – key findings

 

clinical-stage biotechnology company